N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C.H. Choi, M. Rabaglio, Frederik Marmé, E. Petru, C-H. Lai, E. Biagioli, L. Fariñas-Madrid, K. Takehara, K. Allan, Yeh Chen Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero, M. Barretina-Ginesta
{"title":"546 AtTEnd/ENGOT-EN7:atezolizumab联合卡铂和紫杉醇治疗晚期/复发性子宫内膜癌妇女的III期双盲随机安慰剂对照试验","authors":"N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C.H. Choi, M. Rabaglio, Frederik Marmé, E. Petru, C-H. Lai, E. Biagioli, L. Fariñas-Madrid, K. Takehara, K. Allan, Yeh Chen Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero, M. Barretina-Ginesta","doi":"10.1136/ijgc-2024-esgo.27","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"49 27","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"546 AtTEnd/ENGOT-EN7: phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma\",\"authors\":\"N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C.H. Choi, M. Rabaglio, Frederik Marmé, E. Petru, C-H. Lai, E. Biagioli, L. Fariñas-Madrid, K. Takehara, K. Allan, Yeh Chen Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero, M. Barretina-Ginesta\",\"doi\":\"10.1136/ijgc-2024-esgo.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"49 27\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
546 AtTEnd/ENGOT-EN7: phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma